Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LV5FU2 vs FOLFOX in Esophageal Squamous Cell Carcinoma
NCT01467921Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Dec 2010
- Primary completion
- Feb 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Disease-Free Survival at 36 months. Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01467921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01467921.